$46.60
−1.92%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
14.9x
EV/EBITDA
7.9x
Market Cap
$208.07B
MomentumView details →
1D Return
−1.92%
YTD Return
−8.41%
RSI (14)
49.1
ValuationView details →
P/E (Fwd)
14.9x
EV/EBITDA
7.9x
Market Cap
$208.07B
RSI (14)
49.1
MomentumView details →
1D Return
−1.92%
YTD Return
−8.41%
SummaryUpdated Jun 1, 2026
Novo Nordisk A/S (NYSE:NVO) is a Danish multinational pharmaceutical company founded in 1923 and headquartered in Bagsvaerd, Denmark. The company has evolved from its origins as an insulin manufacturer into a global leader in diabetes care and, more recently, obesity treatment. Novo Nordisk went public in 1981 and has grown to serve over 45 million patients worldwide with diabetes and obesity treatments. The company operates primarily through two business segments: Diabetes and Obesity Care, and Rare Disease, with the former representing the vast majority of its revenue and growth trajectory.
Similar companies
Latest newsMore news →
Novo Nordisk halted two additional trials of its experimental cardiovascular drug ziltivekimab on Monday, September 7, 2026.17h agoNovo Nordisk halted two cardiovascular trials (HERMES and ATHENA) of its drug ziltivekimab after a data monitoring committee found they were unlikely to succeed, following the earlier failure of the ZEUS trial.18h agoNovo Nordisk announced Phase 3 STEP YOUNG clinical data showing that 40.4% of obese children treated with semaglutide plus lifestyle intervention achieved BMI below the obesity threshold.19h ago